Evogene Stock Analysis

EVGN Stock  USD 0.61  0.03  4.69%   
Evogene is undervalued with Real Value of 1.38 and Target Price of 3.62. The main objective of Evogene stock analysis is to determine its intrinsic value, which is an estimate of what Evogene is worth, separate from its market price. There are two main types of Evogene's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Evogene's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Evogene's stock to identify patterns and trends that may indicate its future price movements.
The Evogene stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Evogene is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Evogene Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Evogene's ongoing operational relationships across important fundamental and technical indicators.
  
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.

Evogene Stock Analysis Notes

The book value of the company was currently reported as 0.24. The company recorded a loss per share of 0.52. Evogene had not issued any dividends in recent years. The entity had 1:2 split on the 19th of November 2013. Evogene Ltd., together with its subsidiaries, operates as a computational biology company. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel. Evogene operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 133 people. To learn more about Evogene call Ofer CPA at 972 8 931 1900 or check out https://www.evogene.com.

Evogene Quarterly Total Revenue

578,000

Evogene Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Evogene's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Evogene or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Evogene generated a negative expected return over the last 90 days
Evogene has some characteristics of a very speculative penny stock
Evogene has high historical volatility and very poor performance
The company reported the previous year's revenue of 5.64 M. Net Loss for the year was (23.88 M) with profit before overhead, payroll, taxes, and interest of 766 K.
Evogene currently holds about 35.25 M in cash with (21.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.86, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Evogene has a frail financial position based on the latest SEC disclosures
Latest headline from news.google.com: Lavie Bio to Host a Round Table Discussion and is a Sponsor at World Agri-Tech Conference in San Francisco - The Globe and Mail

Evogene Upcoming and Recent Events

Earnings reports are used by Evogene to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Evogene previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
14th of March 2024
Upcoming Quarterly Report
View
16th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Evogene Largest EPS Surprises

Earnings surprises can significantly impact Evogene's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2022-03-10
2021-12-31-0.2-0.180.0210 
2021-11-17
2021-09-30-0.17-0.19-0.0211 
2018-05-29
2018-03-31-0.19-0.21-0.0210 
View All Earnings Estimates

Evogene Thematic Classifications

In addition to having Evogene stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Chemicals Idea
Chemicals
USA Equities from Chemicals industry as classified by Fama & French

Evogene Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Evogene is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Evogene backward and forwards among themselves. Evogene's institutional investor refers to the entity that pools money to purchase Evogene's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Joel Isaacson & Co., Llc2023-12-31
30.3 K
Citadel Advisors Llc2023-09-30
27.5 K
Susquehanna International Group, Llp2023-12-31
24.3 K
Sigma Planning Corp2023-12-31
23.1 K
Pnc Financial Services Group Inc2023-12-31
22.3 K
Private Advisor Group, Llc2023-12-31
14 K
Two Sigma Securities, Llc2023-12-31
12.4 K
Malaga Cove Capital, Llc2023-12-31
12 K
Sns Financial Group, Llc2023-12-31
10 K
Silverarc Capital Management, Llc2023-12-31
3.1 M
Walleye Trading Advisors, Llc2023-12-31
349.5 K
Note, although Evogene's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Evogene Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 32.72 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Evogene's market, we take the total number of its shares issued and multiply it by Evogene's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Evogene Profitablity

Evogene's profitability indicators refer to fundamental financial ratios that showcase Evogene's ability to generate income relative to its revenue or operating costs. If, let's say, Evogene is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Evogene's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Evogene's profitability requires more research than a typical breakdown of Evogene's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.63)(0.66)
Return On Capital Employed(0.60)(0.63)
Return On Assets(0.47)(0.49)
Return On Equity(1.98)(1.88)

Management Efficiency

Evogene has return on total asset (ROA) of (0.309) % which means that it has lost $0.309 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8178) %, meaning that it created substantial loss on money invested by shareholders. Evogene's management efficiency ratios could be used to measure how well Evogene manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of April 2024, Return On Tangible Assets is likely to drop to -0.66. In addition to that, Return On Capital Employed is likely to drop to -0.63. At this time, Evogene's Total Assets are very stable compared to the past year. As of the 19th of April 2024, Non Currrent Assets Other is likely to grow to about 28.4 K, while Other Assets are likely to drop 0.95.
Last ReportedProjected for Next Year
Book Value Per Share 0.26  0.25 
Net Current Asset Value 0.00  0.00 
Tangible Asset Value 0.00  0.00 
Tangible Book Value Per Share 0.44  0.41 
Enterprise Value Over EBITDA(0.79)(0.83)
Price Book Value Ratio 3.18  2.16 
Enterprise Value Multiple(0.79)(0.83)
Price Fair Value 3.18  2.16 
Enterprise Value18.7 M17.8 M
The analysis of Evogene's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Evogene's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Evogene Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta
1.164

Technical Drivers

As of the 19th of April, Evogene shows the Mean Deviation of 3.19, variance of 22.96, and Standard Deviation of 4.79. Evogene technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze and collect data for thirteen technical drivers for Evogene, which can be compared to its peers. Please confirm Evogene variance and potential upside to decide if Evogene is priced favorably, providing market reflects its regular price of 0.61 per share. As Evogene is a penny stock we also recommend to verify its jensen alpha numbers.

Evogene Price Movement Analysis

Execute Study
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Evogene middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Evogene. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Evogene Predictive Daily Indicators

Evogene intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Evogene stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Evogene Forecast Models

Evogene's time-series forecasting models are one of many Evogene's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Evogene's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Evogene Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Evogene prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Evogene shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Evogene. By using and applying Evogene Stock analysis, traders can create a robust methodology for identifying Evogene entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(4.61)(4.84)
Operating Profit Margin(4.68)(4.91)
Net Loss(4.23)(4.45)
Gross Profit Margin 0.25  0.36 

Current Evogene Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Evogene analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Evogene analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
3.62Strong Buy1Odds
Evogene current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Evogene analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Evogene stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Evogene, talking to its executives and customers, or listening to Evogene conference calls.
Evogene Analyst Advice Details

Evogene Stock Analysis Indicators

Evogene stock analysis indicators help investors evaluate how Evogene stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Evogene shares will generate the highest return on investment. By understating and applying Evogene stock analysis, traders can identify Evogene position entry and exit signals to maximize returns.
Begin Period Cash Flow29 M
Long Term Debt10.4 M
Common Stock Shares Outstanding45.7 M
Total Stockholder Equity12.1 M
Tax Provision16 K
Property Plant And Equipment Net3.4 M
Cash And Short Term Investments31.1 M
Cash20.8 M
Accounts Payable1.8 M
Net Debt-19.6 M
50 Day M A0.8062
Total Current Liabilities6.9 M
Other Operating Expenses32 M
Non Current Assets Total16.6 M
Non Currrent Assets Other28 K
Stock Based Compensation1.9 M
When determining whether Evogene offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Evogene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Evogene Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Evogene Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.
Note that the Evogene information on this page should be used as a complementary analysis to other Evogene's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Complementary Tools for Evogene Stock analysis

When running Evogene's price analysis, check to measure Evogene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evogene is operating at the current time. Most of Evogene's value examination focuses on studying past and present price action to predict the probability of Evogene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evogene's price. Additionally, you may evaluate how the addition of Evogene to your portfolios can decrease your overall portfolio volatility.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
CEOs Directory
Screen CEOs from public companies around the world
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Is Evogene's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evogene. If investors know Evogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evogene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.52)
Revenue Per Share
0.123
Quarterly Revenue Growth
(0.12)
Return On Assets
(0.31)
Return On Equity
(0.82)
The market value of Evogene is measured differently than its book value, which is the value of Evogene that is recorded on the company's balance sheet. Investors also form their own opinion of Evogene's value that differs from its market value or its book value, called intrinsic value, which is Evogene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evogene's market value can be influenced by many factors that don't directly affect Evogene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.